Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

20.47 -0.01 (-0.05%)
Streaming Delayed Price Updated: 10:08 AM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,279
Open 20.51
Bid (Size) 20.36 (1,100)
Ask (Size) 20.54 (200)
Prev. Close 20.48
Today's Range 20.47 - 20.64
52wk Range 14.00 - 23.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Oculis Holding AG (NASDAQ:OCS) Reports Q3 2025 Earnings Beat and Provides Key Clinical Pipeline Updates ↗
Oculis (OCS) beat Q3 2025 earnings estimates, extended cash runway into 2029, and advanced its late-stage ophthalmology pipeline with key clinical milestones ahead. 
Via Chartmill
Topics Earnings

Performance

YTD
+20.9%
+20.9%
1 Month
+6.1%
+6.1%
3 Month
+15.3%
+15.3%
6 Month
+3.6%
+3.6%
1 Year
+21.7%
+21.7%

More News

Read More
News headline image
Oculis Reports Q3 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Oculis to Participate in Upcoming November Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Uncovering Potential: Oculis Holding's Earnings Preview ↗
Via Benzinga
News headline image
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming September Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
This CoreWeave Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q2 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Earnings Scheduled For August 21, 2025 ↗
Via Benzinga
News headline image
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Upsized Loan Facility to Access up to CHF 100 million
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Results of 2025 Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Participate in Upcoming June Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
News headline image
Dave To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday ↗
Via Benzinga
News headline image
Oculis Reports Q1 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire

Frequently Asked Questions

Is Oculis Holding AG - Ordinary shares publicly traded?
Yes, Oculis Holding AG - Ordinary shares is publicly traded.
What exchange does Oculis Holding AG - Ordinary shares trade on?
Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oculis Holding AG - Ordinary shares?
The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
What is the current price of Oculis Holding AG - Ordinary shares?
The current price of Oculis Holding AG - Ordinary shares is 20.47
When was Oculis Holding AG - Ordinary shares last traded?
The last trade of Oculis Holding AG - Ordinary shares was at 12/24/25 10:08 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.